Market Cap 22.20B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 958,400
Avg Vol 1,041,012
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 31%
Beta 1.36
Analysts Strong Sell
Price Target $133.11

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
eightytwentie
eightytwentie May. 22 at 12:24 AM
$BNTX https://www.asco.org/abstracts-presentations/261380
0 · Reply
eightytwentie
eightytwentie May. 21 at 11:58 PM
$BNTX poontang getting that ORR 72.7%
0 · Reply
eightytwentie
eightytwentie May. 21 at 11:57 PM
$BNTX poontangmiggg let’s goooo
0 · Reply
SoYeonPicks
SoYeonPicks May. 21 at 11:16 PM
$BNTX great Phase 2 data from ROSETTA Lung-02!!
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 21 at 9:25 PM
$BNTX let’s go
0 · Reply
eightytwentie
eightytwentie May. 21 at 9:15 PM
$BNTX yes https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Unveil-New-Data-at-ASCO-2026-Demonstrating-Strength-and-Breadth-of-Scientific-Innovation-Across-Oncology-Portfolio-and-Next-Generation-Pipeline/default.aspx
0 · Reply
Estimize
Estimize May. 21 at 11:03 AM
Wall St is expecting -2.44 EPS for $BNTX Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_c
0 · Reply
OnlyFibs
OnlyFibs May. 21 at 2:37 AM
$BNTX$600K in $95C expiring 6/18 BioNTech. $3.83 avg. 4 weeks. mRNA cancer vaccine pipeline. Someone expects a specific near-term catalyst before June 18. 🐂 Pipeline catalyst hits and this prints. $600K says they expect something specific. 🐻 4 weeks no catalyst = premium gone. ⚠️ Near-term BioNTech call flow right as the mRNA space heats up. #hovdid 📊 Lean: BULL — binary. Catalyst shows or it doesn't.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 21 at 2:25 AM
$BNTX With so bullish catalysts for cancer clinical pipeline milestone readouts, this stock could be $180 - $270 by the end of this year. Yes, double or triple current price. JMO
0 · Reply
SoYeonPicks
SoYeonPicks May. 20 at 10:46 PM
$BNTX big things coming
0 · Reply
Latest News on BNTX
BioNTech initiated with a Market Perform at Bernstein

2026-05-21T20:27:55.000Z - 4 hours ago

BioNTech initiated with a Market Perform at Bernstein


BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 6 days ago

BioNTech SE Transcript: AGM 2026


BioNTech announces new $1B ADS repurchase program

2026-05-07T14:04:55.000Z - 14 days ago

BioNTech announces new $1B ADS repurchase program


BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 14 days ago

BioNTech Announces New ADS Repurchase Program


BioNTech price target lowered to $158 from $171 at Canaccord

2026-05-07T07:26:08.000Z - 14 days ago

BioNTech price target lowered to $158 from $171 at Canaccord


BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Earnings Call Transcript: Q1 2026


BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Earnings release: Q1 2026


BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 16 days ago

BioNTech SE Slides: Q1 2026


BioNTech reaffirms FY26 revenue view EUR2.000B- EUR2.300B

2026-05-05T11:14:49.000Z - 16 days ago

BioNTech reaffirms FY26 revenue view EUR2.000B- EUR2.300B


BioNTech price target raised to $130 from $128 at BofA

2026-04-13T12:01:10.000Z - 5 weeks ago

BioNTech price target raised to $130 from $128 at BofA


BioNTech price target lowered to $94 from $116 at TD Cowen

2026-03-11T12:10:41.000Z - 2 months ago

BioNTech price target lowered to $94 from $116 at TD Cowen


BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Earnings Call Transcript: Q4 2025


BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Annual report: Q4 2025


BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Earnings release: Q4 2025


BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 2 months ago

BioNTech SE Slides: Q4 2025


Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 2 months ago

Scientists behind COVID-19 vaccine will depart BioNTech


BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 2 months ago

BioNTech Cofounders to Leave to Form New Company


BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 6 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE


BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 6 months ago

BioNTech SE Transcript: R&D Day


BioNTech SE Slides: R&D Day

Nov 11, 2025, 9:00 AM EST - 6 months ago

BioNTech SE Slides: R&D Day


BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

BioNTech SE Earnings Call Transcript: Q3 2025


BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

BioNTech SE Earnings release: Q3 2025


BioNTech SE Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 7 months ago

BioNTech SE Slides: Q3 2025


BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 7 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment


BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 7 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025


BioNTech SE Transcript: AI Day 2025

Oct 1, 2025, 9:00 AM EDT - 8 months ago

BioNTech SE Transcript: AI Day 2025


BioNTech SE Slides: FY 2025

Oct 1, 2025, 9:00 AM EDT - 8 months ago

BioNTech SE Slides: FY 2025


BioNTech SE Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 10 months ago

BioNTech SE Earnings Call Transcript: Q2 2025


BioNTech SE Earnings release: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 10 months ago

BioNTech SE Earnings release: Q2 2025


BioNTech SE Slides: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 10 months ago

BioNTech SE Slides: Q2 2025


BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 10 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.


eightytwentie
eightytwentie May. 22 at 12:24 AM
$BNTX https://www.asco.org/abstracts-presentations/261380
0 · Reply
eightytwentie
eightytwentie May. 21 at 11:58 PM
$BNTX poontang getting that ORR 72.7%
0 · Reply
eightytwentie
eightytwentie May. 21 at 11:57 PM
$BNTX poontangmiggg let’s goooo
0 · Reply
SoYeonPicks
SoYeonPicks May. 21 at 11:16 PM
$BNTX great Phase 2 data from ROSETTA Lung-02!!
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 21 at 9:25 PM
$BNTX let’s go
0 · Reply
eightytwentie
eightytwentie May. 21 at 9:15 PM
$BNTX yes https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-to-Unveil-New-Data-at-ASCO-2026-Demonstrating-Strength-and-Breadth-of-Scientific-Innovation-Across-Oncology-Portfolio-and-Next-Generation-Pipeline/default.aspx
0 · Reply
Estimize
Estimize May. 21 at 11:03 AM
Wall St is expecting -2.44 EPS for $BNTX Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_c
0 · Reply
OnlyFibs
OnlyFibs May. 21 at 2:37 AM
$BNTX$600K in $95C expiring 6/18 BioNTech. $3.83 avg. 4 weeks. mRNA cancer vaccine pipeline. Someone expects a specific near-term catalyst before June 18. 🐂 Pipeline catalyst hits and this prints. $600K says they expect something specific. 🐻 4 weeks no catalyst = premium gone. ⚠️ Near-term BioNTech call flow right as the mRNA space heats up. #hovdid 📊 Lean: BULL — binary. Catalyst shows or it doesn't.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 21 at 2:25 AM
$BNTX With so bullish catalysts for cancer clinical pipeline milestone readouts, this stock could be $180 - $270 by the end of this year. Yes, double or triple current price. JMO
0 · Reply
SoYeonPicks
SoYeonPicks May. 20 at 10:46 PM
$BNTX big things coming
0 · Reply
WallStJesus
WallStJesus May. 20 at 2:13 PM
$BNTX BULL BET ..
0 · Reply
taxplanr
taxplanr May. 20 at 1:31 PM
Cancer free in 9 months with Ivermectin and Fenbendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-f61?utm_source=post-email-title&publication_id=1385328&post_id=197939877&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
htw7448
htw7448 May. 19 at 3:35 PM
$BNTX wake up call for the keytruda killer
0 · Reply
htw7448
htw7448 May. 19 at 2:19 PM
$BNTX big keytruda fuck incoming :)
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 12:08 PM
$BMY $BNTX $IBRX $SPY let’s go BioNTech
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 11:18 AM
$BNTX anyone expecting we will rally hard on Thursday after 5?
2 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 11:09 AM
$BNTX good find
0 · Reply
htw7448
htw7448 May. 19 at 9:25 AM
$BNTX a lot of new information on 30 th of may. https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/program-guide/scheduled-sessions/search?q=biontech
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 19 at 2:25 AM
$BMY $BNTX $IBRX $SPY let’s go
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 18 at 11:01 PM
$BNTX $SPY $BMY $IBRX https://www.reddit.com/r/wallstreetbets/s/xX6Y6Zx50Q
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 18 at 9:38 PM
$BNTX Additional lung cancer–focused BioNTech abstracts referenced in 2026 conference coverage include: * “First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Monotherapy in PD-L1+ Non-Squamous and Squamous Non-Small Cell Lung Cancer: Data from a Phase 1b/2a Trial in China.” * “Progression-Free Survival and Overall Survival with Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer Following Progression with EGFR TKI in China: Phase 2 Study Results.”
0 · Reply
OPEN_LIFE
OPEN_LIFE May. 18 at 9:38 PM
$BNTX here are the abstracts they submitted * “First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy as first-line treatment in unresectable malignant mesothelioma.” * “DB-1311/BNT324 (a novel B7H3 ADC) in patients with castrate-resistant prostate cancer (CRPC).” * “First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients with CLDN6-positive advanced solid tumors.” * “A global Phase 3 double-blind, randomized trial of BNT327/PM8002 plus chemotherapy compared to atezolizumab plus chemo in patients with first-line extensive-stage small cell lung cancer (ES-SCLC).”
0 · Reply